Lenalidomide up-regulates SPARC and inhibits in vitro growth of the malignant clone in myelodysplastic syndrome patients with 5q deletion.

Míreanna comhchosúla

• Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
  de réir: Pellagatti, A, et al.
  Foilsithe / Cruthaithe: (2007)
• Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.
  de réir: Jadersten, M, et al.
  Foilsithe / Cruthaithe: (2005)
• Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
  de réir: Jädersten, M, et al.
  Foilsithe / Cruthaithe: (2009)
• Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression
  de réir: Martin Jädersten, et al.
  Foilsithe / Cruthaithe: (2009-12-01)
• Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment
  de réir: Scharenberg, C, et al.
  Foilsithe / Cruthaithe: (2011)